Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience

Cavalieri Stefano; Di Guardo Lorenza; Cimminiello Carolina; Bono Aldo; Tolomio Elena; Colombetti Anna; Valeri Barbara; Di Tolla Giuseppe; de Braud Filippo; Del Vecchio Michele

首页> 外文期刊>Tumori. >Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience

【24h】

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience

机译：在现实生活中，结合达拉非尼和曲美替尼联合治疗BRAF突变的转移性黑色素瘤：INT米兰体验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Combination therapy with dabrafenib and trametinib is safer and more effective than BRAF inhibitor-based monotherapy for metastatic melanoma.

机译：目的：与基于BRAF抑制剂的单药治疗转移性黑色素瘤相比，达布拉非尼和曲美替尼联合治疗更安全，更有效。

著录项

来源
《Tumori.》 |2016年第5期|共7页
作者
Cavalieri Stefano; Di Guardo Lorenza; Cimminiello Carolina; Bono Aldo; Tolomio Elena; Colombetti Anna; Valeri Barbara; Di Tolla Giuseppe; de Braud Filippo; Del Vecchio Michele;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
BRAF; Dabrafenib; MEK; Melanoma; Targeted therapy; Trametinib;

机译：BRAF;达拉非尼;MEK;黑色素瘤;靶向治疗;曲美替尼;

相似文献

外文文献
中文文献
专利

1. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience [J] . Cavalieri Stefano, Di Guardo Lorenza, Cimminiello Carolina, Tumori. . 2016,第5期

机译：在现实生活中，结合达拉非尼和曲美替尼联合治疗BRAF突变的转移性黑色素瘤：INT米兰体验
2. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting [J] . Matter-Walstra K., Braun R., Kolb C., British Journal of Dermatology . 2015,第6期

机译：曲美替尼联合达布拉非尼作为转移性BRAF V600突变型黑素瘤一线治疗在瑞士的成本效益分析
3. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) [J] . Igor Puzanov Journal of Translational Medicine . 2015,第SUPPLEMENTa1期

机译：结合靶向治疗和免疫治疗：BRAF抑制剂dabrafenib（D）±MEK抑制剂曲美替尼（T）与ipilimumab（Ipi）联合治疗V600E / K突变阳性的不可切除或转移性黑色素瘤（MM）
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Predicting Response to Anti-PD-1 Immunotherapy in Metastatic Melanoma. [D] . Smithy, James William. 2017

机译：预测转移性黑色素瘤中抗PD-1免疫疗法的反应。
6. Comparative safety of BRAF and MEK inhibitors (vemurafenib dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma [O] . Ana Cebollero, Teresa Puértolas, Isabel Pajares, -1

机译：BRAF和MEK抑制剂（vemurafenibdabrafenib和曲美替尼）在BRAF突变的转移性黑色素瘤一线治疗中的比较安全性
7. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting [O] . Matter-Walstra, K, Braun, R, Kolb, C, 2015

机译：曲美替尼联合达布拉非尼作为转移性BRAF V600突变型黑色素瘤一线治疗在瑞士的成本效益分析

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience

摘要

著录项

相似文献

相关主题

期刊订阅